Frankfurt
27.06.25 | 08:07
0,803 Euro
-1,83 % -0,015
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | DIAMYD MEDICAL AB: Quarterly Report 3 24/25 | 2 | Cision News | ||
| Mi | Diamyd Medical AB (publ): Quarterly Report 3 24/25 | 56 | GlobeNewswire (Europe) | Precision Medicine for Autoimmune Diabetes
Aiming for Accelerated Market Approval
Autoimmune or Type-1 Diabetes (T1D) is a progressive disease, diagnosed as at least two antibodies to the insulin producing... ► Artikel lesen | |
| 16.06. | DIAMYD MEDICAL AB: Diamyd Medical to participate in two key US diabetes events | 11 | Cision News | ||
| 19.05. | Diamyd Medical AB (publ): Diamyd Medical appoints Niklas Axelsson as CFO | 117 | GlobeNewswire (Europe) | Niklas Axelsson has been appointed CFO of Diamyd Medical. He will assume his position in August and will also join the management team. Niklas Axelsson brings more than 25 years of experience across... ► Artikel lesen | |
| DIAMYD MEDICAL Aktie jetzt für 0€ handeln | |||||
| 15.05. | DIAMYD MEDICAL AB: Adjustment of the number of shares and share capital in Diamyd Medical, receives SEK 1.6 million more than previously communicated | 4 | Cision News | ||
| 05.05. | DIAMYD MEDICAL AB: Diamyd Medical has expanded the recently completed rights issue with a directed new issue of SEK 41.6 million | 8 | Cision News | ||
| 30.04. | DIAMYD MEDICAL AB: Diamyd Medical announces final outcome in oversubscribed rights issue: SEK 224 million | 3 | Cision News | ||
| 30.04. | DIAMYD MEDICAL AB: Diamyd Medical updates the preliminary outcome and will exercise the additional unit issue following the oversubscribed rights issue, raising approximately SEK 224 million | 2 | Cision News | ||
| 29.04. | DIAMYD MEDICAL AB: Diamyd Medical's rights issue has been preliminarily subscribed to 95 percent, thereby raising approximately SEK 198 million | 1 | Cision News | ||
| 28.04. | DIAMYD MEDICAL AB: Last day of the subscription period in Diamyd Medicals rights issue | 1 | Cision News | ||
| 28.04. | DIAMYD MEDICAL AB: Europe to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in autoimmune diabetes | 1 | Cision News | ||
| 25.04. | Diamyd Medical AB (publ): Diamyd Medical's pivotal Phase 3 Type 1 Diabetes trial clears second-to-last safety review ahead of early readout in March 2026 | 113 | GlobeNewswire (Europe) | The independent Data Safety Monitoring Board (DSMB) has completed its fifth scheduled safety review of Diamyd Medical's registrational Phase 3 trial, DIAGNODE-3, evaluating the precision medicine immunotherapy... ► Artikel lesen | |
| 22.04. | DIAMYD MEDICAL AB: Shareholders in Diamyd Medical, including the Chairman of the Board, have provided additional subscription commitments in the ongoing rights issue | 2 | Cision News | ||
| 21.04. | Diamyd Medical AB: Diamyd Medical highlights opportunity in Type 1 Diabetes prevention, adult-onset market, and upcoming Phase 3 readout | 304 | PR Newswire | STOCKHOLM, April 21, 2025 /PRNewswire/ -- In a recent investor interview, Diamyd Medical Board Member Professor Mark Atkinson and CEO Ulf Hannelius shared key insights into the Company's... ► Artikel lesen | |
| 17.04. | DIAMYD MEDICAL AB: The prevention trial DiaPrecise with Diamyd® clears first safety milestone | 1 | Cision News | ||
| 15.04. | Diamyd Medical AB (publ): Australia grants Diamyd Medical patent for novel antigen combination in autoimmune diabetes treatment | 148 | GlobeNewswire (Europe) | The Australian Patent Office has granted a patent protecting a novel immunotherapeutic composition developed by Diamyd Medical for use in the treatment and prevention of autoimmune diabetes. The patent... ► Artikel lesen | |
| 14.04. | DIAMYD MEDICAL AB: Diamyd Medical publishes prospectus with regards to the rights issue | 1 | Cision News | ||
| 09.04. | Diamyd Medical AB (publ): Quarterly Report 2 24/25 | 136 | GlobeNewswire (Europe) | Diamyd Medical today announces in its second quarterly report for fiscal year 2024/2025 continued progress toward a transformative regulatory milestone, with early Phase 3 results from the DIAGNODE-3... ► Artikel lesen | |
| 09.04. | XFRA CAPITAL ADJUSTMENT INFORMATION - 09.04.2025 | 148 | Xetra Newsboard | Das Instrument N7S CA87043J2039 SWEET POISON SPIRITS INC. EQUITY wird cum Kapitalmassnahme gehandelt am 09.04.2025 und ex Kapitalmassnahme am 10.04.2025 The instrument N7S CA87043J2039 SWEET POISON... ► Artikel lesen | |
| 21.03. | DIAMYD MEDICAL AB: Diamyd Medical announces additional subscription commitments for upcoming rights issue | 1 | Cision News |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 155,40 | -0,26 % | Aktienmarkt: Kurs der Aktie von AbbVie im Plus (159,9573 €) | Die Aktie von AbbVie notiert heute ein wenig fester. Das Papier kostete zuletzt 185,88 US-Dollar. Der Anteilsschein von AbbVie verzeichnet zur Stunde einen Preisanstieg von 1,15 Prozent. Er hat sich... ► Artikel lesen | |
| INNOCAN PHARMA | 0,145 | +2,11 % | Breaking News: Innocan Pharma - der Superstar auf der "PAINWEEK"? | ||
| ABBOTT LABORATORIES | 114,48 | -0,24 % | Abbott in partnership focused on producing pharmaceuticals in Abu Dhabi | ||
| ARZNEIWERK AG VIDA | 0,575 | -5,74 % | PTA-News: Arzneiwerk AG VIDA: Börsenzulassung von 226.155 Aktien | DJ PTA-News: Arzneiwerk AG VIDA: Börsenzulassung von 226.155 Aktien
Unternehmensmitteilung für den Kapitalmarkt
Arzneiwerk AG VIDA: Börsenzulassung von 226.155 Aktien
Berlin (pta000/16.06.2025/12:00... ► Artikel lesen | |
| ZOETIS | 133,20 | -0,15 % | Minimales Kursplus bei der Zoetis-Aktie (142,2837 €) | Wenig Kursbewegung aktuell bei dem Anteilsschein von Zoetis . Das Papier kostete zuletzt 164,83 US-Dollar. Der Kurs der Aktie von Zoetis zeigt sich gegenwärtig kaum verändert im Vergleich zu der letzten... ► Artikel lesen | |
| CRESCO LABS | 0,450 | +6,18 % | Cresco Labs Inc: Cresco Labs terminates auditor Marcum | ||
| CSPC PHARMA | 0,855 | +1,23 % | CSPC PHARMA (01093): NOMINATION COMMITTEE - TERMS OF REFERENCE | ||
| TONIX PHARMACEUTICALS | 29,000 | -2,68 % | Pre-market Movers: Creative Global Technology, Liminatus Pharma, CureVac, Jupiter Neurosciences, Tonix Pharmaceuticals | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.05 A.M. ET).In the Green Creative Global Technology Holdings Limited (CGTL)... ► Artikel lesen | |
| AMARIN | 13,200 | +0,76 % | Recordati: RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA IN EUROPE | RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE
Vazkepa® supported by strong clinical data package and expected to contribute to Specialty... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 22,500 | +1,81 % | XFRA ITH0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILNEKTAR THERAP. NEW... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 89,44 | +1,25 % | Axsome Therapeutics, Inc.: Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia | NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today... ► Artikel lesen | |
| WUXI BIOLOGICS | 2,743 | +1,59 % | Aktie von WuXi Biologics büßt 3,05 Prozent ein (2,6755 €) | Am Aktienmarkt liegt der Anteilsschein von WuXi Biologics zur Stunde im Minus. Das Wertpapier kostete zuletzt 2,68 Euro. Im Wertpapierhandel hat sich heute die Aktie von WuXi Biologics zwischenzeitlich... ► Artikel lesen | |
| JAGUAR HEALTH | 2,500 | -7,75 % | Jaguar Health, Inc.: Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset | Strategic decision positions Jaguar to diversify treasury holdings with a long-term digital store of value SAN FRANCISCO, CA / ACCESS Newswire / June 26, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar"... ► Artikel lesen | |
| DAIICHI SANKYO | 19,690 | -0,88 % | AstraZeneca To Pay $45 Mln To Daiichi Sankyo As Datroway Gets FDA Approval For Lung Cancer | LONDON (dpa-AFX) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Tuesday that the U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan or Dato-DXd), co-developed... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 18,695 | -1,03 % | Acadia's 'very bullish' sales forecast restores some confidence on Wall Street |
DIAMYD MEDICAL AB gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 0,803 Euro und damit -1,83 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAMYD MEDICAL AB finden Sie auf Wallstreet Online.